PR Newswire Clinical TrialsOriginal article
TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up
Phase 1positiveTTX-MC138Positive
AI Analysis
Summary
TransCode reported continued positive efficacy data from its ongoing Phase 1a trial of TTX-MC138, demonstrating 71.4% stable disease rate and sustained disease control in heavily pretreated patients with advanced solid tumors.
Clinical Trial Data
Phase
1a
Primary Endpoint
Met
Patients
14
Outcome Details
71.4% stable disease rate in 14 efficacy-evaluable patients; 57.1% achieved disease control through three months of therapy; 36.7% maintained disease control
Importance:5/10
Sentiment:
0.70
Phase 1asolid tumorsdisease stabilizationheavily pretreated patientsantitumor activity
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on September 28, 2026 12:04 PM